ABSTRACT
In the combined antiretroviral therapy era, HIV-infected patients remain a vulnerable population for the onset of bloodstream infections (BSI). Worldwide, nontyphoid salmonellae, Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus and coagulase negative staphylococci are the most important pathogens. Intravenous catheter associated infection, skin-soft tissue infection and endocarditis are associated with Gram-positive bacteremia. Among the Gram-negative, nontyphoidal Salmonella and Salmonella have been previously correlated to sepsis. Other causes of BSI in HIV-infected patients are mycobacteria and fungi. Mycobacteria constitute a major cause of BSI in limited resource countries. Fungal BSI are not frequent and among them Cryptococcus neoformans is the most common life-threatening infection. The degree of immunosuppression remains the key prognostic factor leading to the development of BSI.

KEYWORDS
AIDS; bacteremia; bloodstream infection; BSI; fungemia; Gram negative; Gram positive; HIV; mycobacteria; sepsis

Introduction
Despite the dramatic reduction of AIDS-related deaths and opportunistic infection rate after the introduction of combined antiretroviral therapy (cART), infection with the human immunodeficiency virus (HIV) remains a cause of increased risk of bloodstream infection (BSI).1-4 HIV-infected patients remain a “fragile” population, even after achieving an acceptable immunological status, as their mortality decreases to levels comparable to the general population only after 6–10 y of immune-recovery and HIV-RNA suppression.5,6 Many factors appear to predispose HIV-infected patients to invasive bacterial and fungal infections; in particular, altered cell-mediated immunity, B-cell dysfunction with consequent lack of serum opsonins as well as qualitative and quantitative deficits of neutrophils.7 HIV-infected patients are not fully immune until the CD4+ cell count increases to >750 cells/μL.8 In HIV-infected patients with CD4 cell count >500 cells/μL the risk of infectious diseases and even of AIDS-defining infections (e.g. recurrent pneumonia and extra-pulmonary tuberculosis) are higher compared to the general population.8 The recent START-INSIGHT trial demonstrated that the CD4 cell count is crucial to define a patient’s immunological status and to establish the timing of cART initiation. Indeed, patients who started cART early had a significantly lower probability of AIDS and non-AIDS events (e.g., bacterial infections), even when their baseline CD4 cell counts was >500 cells/μL.9

Two main factors influence the epidemiology of BSI in HIV-infected patients; the availability of cART, which has determined a reduction of incidence and a change of clinical characteristics of BSI in industrialized countries;10 and the geographic distribution of some pathogens.3 BSI are associated with increased mortality rate, length of hospital stay and intensive care unit (ICU) admission rate.11 BSI are now a more frequent cause of ICU admission than Pneumocystis jiroveci pneumonia in HIV-infected patients.12,13 Nontyphoid salmonella, Streptococcus pneumoniae, Escherichia coli and Staphylococcus aureus are the most important pathogens of BSI. Fungal and mycobacterial infections are less frequent but can have considerable clinical and economic impact. Among the pathogens responsible for BSI, Mycobacteria spp., Cryptococcus neoformans and recurrent nontyphoid salmonella constitute AIDS-defining conditions.14

This review describes the main characteristics of BSI in HIV-infected patients, focusing on the etiology, risk factors and outcome. A major scientific database15 was searched, with the search string (HIV or AIDS) and (bloodstream infection OR sepsis OR fungemia OR bacteremia).

Bacterial BSI
The type and incidence of bacterial BSI in HIV-infected patients depend on the historical period (pre-cART or cART era), the geographic area (developed or
resource-limited countries) and the clinical setting (community or hospital). Table 1 summarizes the frequency and the principal etiologies of bacterial BSI.

### Gram-positive bacteria

#### Streptococcus pneumoniae

Invasive pneumococcal disease (IPD) is an important cause of bacteremia in HIV-infected patients throughout the world. Incidence rates of IPD can be up to 100-fold higher in HIV-infected individuals compared to a non-HIV population with more frequent recurring invasive disease. The relative risk of IPD in HIV-infected patients was estimated to be 24.4 (95% confidence interval, 23.7–25.1) in a recent study. The main risk factors for IPD in the current study were male gender, intravenous drug use, smoking, detectable HIV-RNA and low CD4 cell count. By contrast, the use of cART and a pneumococcal conjugate vaccine have been associated with protection.

The mortality rate observed in HIV-infected patients with pneumococcal bacteremia in the pre-cART era was lower compared to the non–HIV-infected population. This lower mortality rate might be related to several factors, including younger age, lower prevalence of associated comorbidities and decreased inflammatory response, leading to a lower incidence of septic shock. Neither the incidence of BSI sustained by S. pneumoniae in the cART era, nor the mortality rate, decreased significantly. The most important factors related to high mortality rate remain low CD4 cell count and the severity of pneumococcal disease (e.g. intensive care unit admission and sepsis). In the cART era, however, HIV-infected patients are aging and this constitutes an independent risk factor for IPD. Moreover, the advanced age of these patients implies an increasing incidence of comorbidities, including kidney diseases, diabetes and cardiovascular disease, which are well-known risk factors for pneumococcal infection in the general population.

The lack of improvement in the mortality rate with the introduction of cART underlines the need for an effective preventive vaccination strategy but data on the 23-valent pneumococcal vaccine are scarce. The vaccine antibody response appears to be related to the CD4 cell count, with a lower response rate at a CD4 count < 200 cells/μL. A multicenter case-control study showed a reduction of IPD ratio only in patients who received vaccination when their CD4 cell count was > 500 cells/μL. Conversely, a study in Uganda when cART was not widely available demonstrated an unexpected increase of IPD in patients vaccinated with the 23-valent vaccine.

### Staphylococcus aureus

S. aureus infections occurs widely in Asia, Europe and the United States, but causes few cases of BSI in Africa. Intravenous catheter, skin-soft tissue infection and endocarditis are significantly associated with Gram-positive BSI. S. aureus epidemiology is influenced by the historical era; S. aureus was the most important pathogen of BSI in a case-control study using all cases of community-acquired BSI identified prospectively in US in the pre-cART era.

---

**Table 1.** Frequencies of causative agents of bloodstream infections and characteristics and outcomes of patients according to the literature.

| Causative Agent | Mean frequency % (range) | Setting of transmission % | Mean number of CD4+ (% of patients) | Outcome (mean crude mortality %) | References |
|-----------------|--------------------------|---------------------------|-----------------------------------|----------------------------------|------------|
| **Bacteria**    |                          |                           |                                   |                                  |            |
| S. aureus       | 12 (2-28)                | 67                        | N.A. N.A.                         | 12                               | 11,32–35,42,54 |
| CONS            | 7 (0-26)                 | 59                        | N.A. N.A.                         | 10                               | 11,32–34,41,42,54 |
| S. pneumoniae   | 13 (0-43)                | 77                        | N.A. N.A.                         | 9                                | 14,19,24,25,32–35,41,42,54,57,58 |
| NTS             | 15 (0-46)                | 80                        | 30 70 95 84 35 32                  | 9                              | 14,19,24,25,32–35,41,42,54,57,58 |
| E.coli          | 8 (0-31)                 | 65                        | N.A. N.A.                         | 15                               | 10,32–35,42,54,57 |
| P.aeruginosa    | 6 (0-30)                 | 50                        | N.A. N.A.                         | 32                               | 10,33–35,42,54 |
| Others          | 24 (10-60)               | 50                        |                                    |                                  |            |
| **Total Bacteria** | 70 (16-100)          |                           |                                    |                                  |            |
| **Mycobacteria** |                          |                           |                                   |                                  |            |
| M. tuberculosis | 17 (0-54)                | 100                       | 0 100 26                           | 48                              | 4,34,42,54,57,58 |
| NTM             | 6 (0-17)                 | 100                       | 0 100 26                           | 48                              | 4,34,42,54,57,58 |
| **Total Mycobacteria** | 20 (0-63)          |                           |                                    |                                  | 48         |
| **Fungi**       |                          |                           |                                   |                                  |            |
| Cryptococcus spp| 5 (0-21)                 | 89                        | N.A. N.A.                         | 26                               | 4,33,34,42,54,56,64 |
| Candida spp     | 1 (0-3)                  | 23                        | 26 84 41                           |                                  | 33,34,54,64,69,70 |
| **Total fungi** | 10 (0-44)                | 78                        | 5 95                               | 35                               | 4,33,34,42,54,57,64,69,70 |
| **Total**       | 78                       | 22                        | 5 95                               | 50 (12-68)                       | 4,10,11,13,32–34,42,54,57 |

Note. CONS: coagulase negative staphylococci; NTS: non typhoidal salmonella; NTM: non tubercular mycobacteria; N.A.: not available.
principal nosocomial BSI pathogen in a Center for Diseases Control multicenter study in which it accounted for 35% of all etiologies. Data for the cART era are controversial. In a prospective study in US, S. aureus was the third most frequent isolate after E. coli and S. pneumoniae, while in a single-hospital study in Spain reporting 67 episodes of Gram-positive BSI (36% of total BSI), S. aureus (10.7%) and coagulase-negative staphylococci (8.6%) were the 2 most frequent pathogens. Definitive positioning is not possible, owing to the paucity of studies available on this topic.

**Methicillin-resistant staphylococcus aureus**

Among people living with HIV, the transmission of community-acquired methicillin-resistant S. aureus (CA-MRSA) is an emerging epidemic, with higher prevalence in healthcare settings. It is documented that the majority of isolates in the largest cohort of HIV-infected patients presenting with S. aureus BSI were CA-MRSA (54%). Moreover, CA-MRSA was associated with increased probability of endocarditis and increased risk of death compared to other S. aureus strains. Studies suggested HIV-infected patients to be at increased risk of CA-MRSA because of overlapping community networks as well as the high prevalence of intravenous drug use (IVDU). IVDU, hemodialysis and CD4 cell count <200 cells/μL are independent risk factors for CA-MRSA. Recent data from a study by Kempkerr et al. suggest an association with advanced age, black ethnicity and AIDS.

**Coagulase-negative staphylococci**

In a recent European study reporting the results of a 10 y survey of BSI in HIV-infected patients, coagulase-negative staphylococci were the principal isolated pathogens. In this study, among 54 episodes of sepsis, 26% were caused by coagulase-negative staphylococci, 20% by Streptococcus pneumoniae and 13% by Enterococcus spp. The most frequent diagnoses in this group were catheter-related BSI and pneumonia. Prior AIDS diagnosis, nadir of CD4 <200 cell/μL and a current CD4 cell count <200 cell/μL were the risk factors. Notably, 56% of these episodes were nosocomial. The 1 and 6 month mortality were 17% and 28%, respectively. Moreover, the Spanish single-hospital study mentioned above reported S. aureus (10.7%) and coagulase-negative staphylococci (8.6%) as the most frequent causative agents of 67 Gram-positive BSI (36% of total BSI). Other studies report lower rates of BSI due to coagulase-negative staphylococci, ranging from 0%–6%.

**Gram-negative bacteria**

Among the Gram-negative bacteria, nontyphoidal Salmonella (NTS) is correlated to HIV infection. NTS refers to infections caused by all serotypes of Salmonella except typhi and paratyphi A, B and C. NTS transmission can occur via the consumption of food or water contaminated with animal feces and, less frequently, through direct contact with infected animals and/or directly between humans. Salmonella infection can have a wide spectrum of clinical presentations: from a self-limiting enterocolitis to a bacteremia with metastatic foci, involving bones, joints, liver, spleen and the meninges. From the beginning of the HIV pandemic, an increased incidence of NTS bacteremia in HIV-infected patients compared to the general population, was described. Indeed, recurrent Salmonella bacteremia was included among the AIDS-defining conditions. Furthermore, NTS bacteremia have high mortality and a tendency to relapse in HIV-infected patients. A prospective study conducted in Malawi in adult patients hospitalized for NTS found that 99% of them were HIV-positive. The inpatient mortality rate was 47%, and 43% of the survivors had a recurrence. Nevertheless, the burden of NTS bacteremia among AIDS-related opportunistic infections has changed over time. Before the introduction of cART, NTS were a major source of BSI and were associated with increased mortality. After 1996, the incidence of recurrent NTS bacteremia decreased significantly among patients who achieved favorable immune-virological response after receiving cART. Hung et al. followed up 93 patients who received a diagnosis of NTS bacteremia from June 1994 to June 2006 in Taiwan. They found that patients who received cART had an incidence of recurrent NTS bacteremia that was significantly lower compared to patients enrolled in the pre-cART era. In particular, the incidence of recurrent NTS bacteremia was 2.56 cases per 100 person-years in the cART era versus 70.56 cases per 100 person-years in the pre-cART era (P < 0.001). Recurrent NTS bacteremia occurred mostly in patients with a low CD4 cell counts in both the pre-cART and the cART era (median CD4 cell count, 8 cells/mL and 20 cells/μL, respectively). Nevertheless, this epidemiologic trend in developed and developing countries is not homogenous. Studies in Africa found NTS is the most frequent Gram-negative isolate, followed by E. coli. A study in Tanzania showed a high prevalence (7.6%) of NTS bacteremia among febrile HIV adult patients admitted at a tertiary hospital compared to non-HIV patients (0.5%), proving NTS BSI to be a common occurrence in this setting. A similar scenario was observed in Asia. In a study of BSI in HIV-infected persons in 2006–2008 in Southeast Asia, Varma et al.
found NTS to be the most common bacterial cause of BSI.53 Likewise, Kiertiburanakul et al. described the pattern of BSI among HIV-infected patients in the cART era in Thailand and found Gram-negative bacteria were the first cause of BSI (39.6%) and, among them, *Salmonella* spp. was the most frequent pathogen (15.6%).54

By contrast, *E. coli* and *P. aeruginosa* are the dominant species among Gram-negative pathogens in Europe and US, and there is a lower rate of *Salmonella* spp. infections.11,30,33

**Escherichia coli and pseudomonas aeruginosa**

In the nosocomial setting, Gram-negative bacteria are a minor source of BSI compared to Gram-positive.55,11,33 In a 12 months multicenter prospective study of patients with advanced HIV infection, Petrosillo et al. found Gram-negative organisms accounting for approximately one-fifth of all BSI and 12.9% of catheter-related BSI. *E. coli* and *P. aeruginosa* were the most frequent Gram-negative isolates.55 Afessa et al. found that Gram-negative bacteria caused 31% of nosocomial bacteremia in hospitalized HIV-infected patients, with *P. aeruginosa* as the most common pathogen.11 Similarly, in a retrospective study by Ortega et al., Gram-negative bacteria caused 31% of nosocomial BSI both in the pre-cART and in the cART era. *P. aeruginosa* and *E. coli* were the most frequently isolated microorganisms in these studies.33

**Mycobacteria**

The isolation of a mycobacterium from a blood culture represents a manifestation of disseminated mycobacterial infection. It can be caused by both tubercular (MTB) and non-tubercular (NTBM) mycobacteria and is typical of immuno-compromised patients. In Western countries BSI caused by mycobacteria are uncommon. Conversely, they are frequent in limited resource settings, like some South-East Asiatic and sub Saharan African countries, where mycobacteria constitute a major cause of sepsis and account for high percentages of positive blood cultures in HIV-infected patients. A mycobacterial infection should be always suspected in HIV-infected patients coming from high prevalence countries. The mycobacteria account for a number of BSI ranging from 17% to 54% of all etiologies in studies performed in endemic areas (Table 1).42,50,53,56-58

This high prevalence may depend on the high frequency of tubercular disease in these geographic areas, as nearly one quarter of the new MTB cases worldwide are estimated to occur in sub-Saharan Africa.59 In addition, advanced HIV disease may play a role. In many countries, especially in those with difficult access to care, HIV infection is often diagnosed in advanced stages, when the number of CD4 cell is extremely low. In the above-mentioned studies, patients diagnosed with mycobacterial BSI had a CD4 cell count <100 cells/μL in most cases with a range of median values between 15 and 129 cells/μL.53,42,54 In this setting, mycobacterial BSI are relatively frequent, not only in cases of overt BSI, but also when the symptoms are less severe, even when pulmonary tuberculosis is considered improbable. In a recent study performed in Malawi, all HIV-infected patients with a CD4 cell count <250 cells/μL and with chronic fever and/or weight loss, but negative smear for mycobacteria, were investigated.56 Among 469 patients, 61 had a positive blood culture and mycobacteria accounted for 24% of all isolated (11 cases of MTB and 4 NTBM). On the other hand, MTB BSI may present as severe sepsis, in which the differential diagnosis between bacterial and mycobacterial origin is challenging. In a study performed in Uganda, nearly 1 in 4 HIV-infected patients hospitalized with severe sepsis had MTB bacteremia.42 In this study, MTB was the commonest etiology of BSI (23.4% of cases), while NTBM constituted 4% of isolates. Several attempts have been made to outline the profile of the typical patients at risk for mycobacterial BSI. They are usually less likely to receive cART,42 with significantly lower median CD4 cell counts,42,54,60 higher HIV RNA,54 fever and cough lasting for > 1 month,60 weight loss of >10 %60 and presence of lymphadenopathies.60 Moreover, they were more likely to have community-acquired infections, were younger compared to patients with bacterial BSI54 and their hemoglobin values were below the median levels.56 Jacob et al. even proposed a score based on male sex, increased heart rate, low CD4 cell count, absence of cART, fever, low serum sodium and low hemoglobin.42 Score higher than 21 points corresponded to a probability of having a diagnosis of MTB bacteremia greater than 70% in the study, but the characteristics considered were not specific, because many of them are present in non-controlled HIV infection also in absence of BSI. Thus, the possibility of such a diagnosis must always be taken into account and cultures for mycobacteria should always be performed, regardless of scores, especially in patients with low CD4 cell count or if there is no response to antibiotic therapy. The majority of mycobacteria infection are caused by TBIM, but in patients with very low CD4 cell count (<50 cells/μL) atypical mycobacteria are also possible and in particular organisms of the *Mycobacterium avium complex* (MAC).61 Likewise to TBIM, MAC BSI are associated with high plasma HIV-RNA levels, but also with previous opportunistic infections and colonization of the respiratory or gastrointestinal tracts.61 The etiological diagnosis is not possible until the result of cultures become positive, but their median time of response exceeds 3 weeks, limiting their role for immediate clinical management.62 The outcome of this kind of infection is poor, and the tubercular etiology of BSI has been found to be a
predictive factor of mortality itself in univariate logistic regression among patients with sepsis. The 30-day mortality rate has been estimated higher than those seen in other BSI in HIV-infected patients, with a mortality rate of about 50% during the hospitalization.

**Fungi**

In the cART era, consistent with the trend registered for bacterial infections, fungal BSI decreased significantly compared to the pre-cART era (Table 1). They constitute a minority of BSI and are found almost exclusively in patients with advanced HIV. The predictive factors of fungal BSI are prior AIDS-defining illness, greater age, lower CD4 cell count and high HIV-RNA. Different fungal species (including Cryptococcus spp., Candida spp., Penicillium marneffei and Histoplasma capsulatum) have been isolated in HIV-infected patients, with higher mortality rates compared to non-HIV-infected patients. Cryptococcosis is the most common life-threatening systemic fungal infection and extrapulmonary cryptococcosis is an AIDS-defining illness. It occurs typically in patients with low compliance with routine medical care and with cART. In a French surveillance study, 1644 cases of cryptococcosis in HIV-infected patients were reviewed. The total number of cases rose steadily until 1995, decreased sharply in 1996 and 1997, and reached a plateau thereafter. In another 12-year study in a tertiary care hospital in Switzerland, 315 patients were diagnosed with fungemia. Among them, 12% were HIV-infected and 35% died within 6 months after fungemia. Cryptococcus spp. and Candida spp were the most frequently identified species. In a retrospective cohort study in Thailand in 2004–2008, data were collected for 140 HIV-infected patients with BSI. Cryptococcus neoformans was the pathogen isolated most frequently (20.8% of cases). Other fungal pathogens, less frequently isolated, were P. marneffei (2.7%) and H. capsulatum (0.7%). Overall, a fungal etiology was proved in 140/140 cases (25%). In the same study, 59% of patients were in CDC clinical stage C and only 36% were on cART. The predictive factors for fungal etiology were older age, focal site infection, kidney insufficiency, higher HIV-RNA and low CD4 cell count. Candidemia in the pre-cART era was a common nosocomial infection in HIV-infected patients hospitalized in ICU, or those with hematological malignancies and neutropenia. In a single-hospital study from 1990 to 1995 in France, the overall mortality was 38% in 13 episodes of candidemia, which was considered a potentially lethal nosocomial complication during late-stage AIDS. A retrospective case control study in the cART era highlighted a significant reduction in the incidence of all cases of hospital-acquired candidemia compared to the pre-cART era. By contrast, the overall mortality rate was higher (59%). Despite the use of cART, candidemia represents a severe complication in advance-stage AIDS.

P. marneffei and H. capsulatum fungemia are common only in the respective endemic areas (Asia and South America) and they must be investigated as probable causative agents in people from those areas, including travelers.

**Conclusions**

BSI in HIV-infected patients have a wide spectrum of possible etiologies, heavily influenced by the geographic area and by the availability of cART. The clinical manifestations are similar to those of control patients; however, the incidence and mortality of BSI are often higher in a HIV population. Higher HIV-RNA, low CD4 cell count and an AIDS-defining condition remain the predictive factors in this setting. Current guidelines recommend the ‘test and treat’ strategy for all HIV-infected people, independently of the CD4 cell count and the clinical stage. Such an approach should result in an increasing HIV population with good immunological status, which will lead to a drop in AIDS-defining conditions. In this scenario, a reduction of BSI due to NTS, Mycobacteria and Cryptococci can be expected. Total disappearance of these conditions is hampered, however, by the ‘late presenter’ issue. Indeed, too many patients still have their HIV status diagnosed in an advanced stage of disease, when their CD4 cell count is already very low. Another factor that will probably have an impact on the rate of BSI in HIV infected patients is the fact that many of them have now the possibility to become older, thus risking the typical problems of elderly people, like cardiovascular disease, hypertension, diabetes mellitus, chronic kidney disease, osteopenia/osteoporosis and non-AIDS defining cancers. These patients, like their HIV-negative counterpart, are at risk of hospitalization and exposure to nosocomial infections; therefore, an increase of nosocomial BSI in HIV patients can be expected. We expect BSI will always be a serious disease with a heavy burden in terms of morbidity and mortality in HIV-infected patients; those with advanced diseases and those in care from a long time and aging with HIV infection represent the highest risk groups.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.
References

[1] Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-8; PMID:10199233; http://dx.doi.org/10.1097/00002030-199902030-00015

[2] Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34; PMID:16878047; http://dx.doi.org/10.1097/01.qai.0000233310.90484.16

[3] Huson MA, Stolp SM, van der Poll T, Grobusch MP. Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review. Clin Infect Dis 2014; 58: 79-92; PMID:24046307; http://dx.doi.org/10.1093/cid/cit596

[4] Mayanja BN, Todd J, Hughes P, Van der Paal L, fi Lewden C, Chene G, Morlat P, Raf fi Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Zurlo JJ, Lane HC. AIDS: etiology, diagnosis, treatment and prevention. 4th ed. Philadelphia: Lippincott-Raven; 1997. Chapter 14.4, Other bacterial infections; p. 259-265

[5] Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C. Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-7; PMID:17621240; http://dx.doi.org/10.1097/QAI.0b013e3181576818

[6] Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psychogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012; 9: 1001194; http://dx.doi.org/10.1371/journal.pmed.1001194

[7] Zurlo JJ, Lane HC. AIDS: etiology, diagnosis, treatment and prevention. 4th ed. Philadelphia: Lippincott-Raven; 1997. Chapter 14.4, Other bacterial infections; p. 259-265

[8] Mocroft A, Raffi H, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayaiy S, Bartmeyer B, Braun D, et al. Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013; 57: 1038-47; PMID:23921881; http://dx.doi.org/10.1093/cid/cit423

[9] INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avhingsanob A, Cooper DA, Fätkenheuer G, Llibre JM, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373: 795-807; PMID:26192873; http://dx.doi.org/10.1056/NEJMoa1506816

[10] Tumbarello M, Tacconelli E, Donati KG, Citton R, Leone F, Spanu T, Cauda R. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr 2000; 23: 145-51; PMID:10737429; http://dx.doi.org/10.1097/0012-3334-20000210-00006

[11] Afessa B, Morales I, Weaver B. Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study. BMC Infect Dis 2001; 1:13; PMID:11602019; http://dx.doi.org/10.1186/1471-2334-1-13

[12] Chiang HH, Hung CC, Lee CM, Chen MY, Sheng WH, Hsieh SM, Sun HY, Ho CC, Yu CJ. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Crit Care 2011; 15: 202; PMID:21345279; http://dx.doi.org/10.1186/cc10419

[13] Rosenberg AL, Seneff MG, Atiyeh L, Wagner R, Bojanowski L, Zimmerman JE. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 2001; 29: 548-56; PMID:11373418; http://dx.doi.org/10.1097/00003246-200103000-00013

[14] Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19

[15] PubMed Health [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2016 Feb 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/

[16] Pedersen RH, Lohse N, Østergaard L, Sogaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12: 323-33; PMID:21059168; http://dx.doi.org/10.1111/j.1468-1293.2010.00892.x

[17] Bliss SJ, O’Brien KL, Janoff EN, Cotton MF, Musoke P, Covadilla H, Levine OS. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8: 67-80; PMID:17974480; http://dx.doi.org/10.1016/S1473-3099(07)70242-6

[18] Harboe ZB, Larsen MV, Ladelund S, Kronborg G, Konradsen HB, Gerstoft J, Larsen C, Pedersen C, Pedersen G, Obel N, et al. Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Infected and Non-HIV-Infected Individuals Before and After the Introduction of Combination Antiretroviral Therapy: Persistent High Risk Among HIV-Infected Injecting Drug Users. Clin Infect Dis 2014; 59: 1168-76; PMID:25038114; http://dx.doi.org/10.1093/cid/ciu558

[19] Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamscher D, Liñares J, Gudiol F. Spanish Pneumococcal Infection Study Network (GO3/103). Epidemiologic changes in bacteremic pneumococcal disease in patients
with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165: 1533-40; PMID:16098870; http://dx.doi.org/10.1001/archinte.165.13.1533

[20] Silva JM Jr, dos Santos S de S. Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics. J Int AIDS Soc 2013; 16: 17344; PMID:23374857; http://dx.doi.org/10.7448/IAS.16.1.17344

[21] Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med. 2000; 132: 182-90; PMID:10651598; http://dx.doi.org/10.7326/0003-4819-132-3-20000201-00003

[22] Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47: 1345-53; PMID:18834317; http://dx.doi.org/10.1097/01.qua.0000285710.1962362

[23] Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117: 314-24; PMID:1637028; http://dx.doi.org/10.7326/0003-4819-117-4-314

[24] Gilks CF, Ojoo SA, Ojoo JC, Brindel RJ, Paul J, Batchelor BJ, Kimari JN, Newnham R, Bwayo J, Plummer FA, et al. Invasive pneumococcal disease in a cohort of predominately HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347: 718-23; PMID:8602624; http://dx.doi.org/10.1016/S0140-6736(96)90076-8

[25] Hibbs JR, Douglas JM Jr, Judson FN, McGill WL, Rietmeijer CA, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis 1997; 25: 195-9; PMID:9332509; http://dx.doi.org/10.1086/514538

[26] Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 857-62; PMID:8603963; http://dx.doi.org/10.1093/infdis/173.4.857

[27] Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE; Adult and Adolescent Spectrum of HIV Disease Project. Twenty-three-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet 2000; 355: 2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1

[28] Archibald LK, Kazembe PN, Nwanyanwu O, Mwasambo C, Reller LB, Jarvis WR. Epidemiology of bloodstream infections in a bacille Calmette-Guérin-vaccinated pediatric population in Malawi. J Infect Dis 2003; 188: 202-8; PMID:12854074; http://dx.doi.org/10.1086/376507

[29] Edge MD, Rimland D. Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole. AIDS 1996; 10: 1635-9; PMID:8970683; http://dx.doi.org/10.1097/00002030-199612000-00007

[30] Hung CC, Hsueh PR, Hsieh SM, Liu CJ, Chen MY, Luh KT. Bacteremia and fungemia in patients with advanced human immunodeficiency virus (HIV) infection in Taiwan. J Formos Med Assoc 1998; 97: 690-7; PMID:9830279

[31] Mootsikapun P. Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast of Thailand. Int J Infect Dis 2007; 11: 226-31; PMID:16815065; http://dx.doi.org/10.1016/j.ijid.2006.02.010

[32] Ortega M, Almela M, Soriano A, Marco F, Martínez JA, Muñoz A, Peñarroja G, Mensa J. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. Eur J Clin Microbiol Infect Dis 2008; 27: 969-76; PMID:18449581; http://dx.doi.org/10.1007/s10096-008-0531-5

[33] Pedro-Botet ML, Moll JM, Valles X, Romeu J, Sopena N, Giménez M, Tor J, CLOTet B, Sabía M. Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995-1997). Int J Infect Dis 2002; 6: 17-22; PMID:12044296; http://dx.doi.org/10.1016/S1201-9712(02)90130-X

[34] Pfe T, Vlieghe E, Reid T, Harries AD, Lim K, Thai S, De Smet B, Veng C, Kham C, Ieng S, et al. Does HIV status affect the aetiology, bacterial resistance patterns and recommended empiric antibiotic treatment in adult patients with bloodstream infection in Cambodia? Trop Med Int Health 2013; 18: 485-94; PMID:23294446; http://dx.doi.org/10.1111/tmi.12060

[35] Stroud L, Srvastava P, Kulver D, Bisno A, Rimland D, Simberkoff M, Elder H, Fierer J, Martone W, Gaynes R. Nosocomial infections in HIV-infected patients: preliminary results from a multicenter surveillance system (1989-1995). Infect Control Hosp Epidemiol 1997; 18: 479-85; PMID:9247830; http://dx.doi.org/10.1086/3011187

[36] Popovich KJ, Weinstein RA, Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 2008; 46: 787-94; PMID:18266611; http://dx.doi.org/10.1086/528716

[37] Furuno JP, Johnson JK, Schweizer ML, Uche A, Stine OC, Shurland SM, Forrest GN. Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study. BMC Infect Dis 2011; 11: 298; PMID:22040268; http://dx.doi.org/10.1186/1471-2334-11-298

[38] Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis J, Gebo KA. The incidence of and risk factors for MRSA bacteremia in an HIV-infected cohort in the HAART era. HIV Med 2008; 9: 858-62; PMID:18754806

[39] Kempker RR, Farley MM, Ladson JL, Satola S, Ray SM. Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia. J Infect 2010; 61: 372-81; PMID:20868707; http://dx.doi.org/10.1016/j.jinf.2010.09.021

[40] Declercq S, De Munter P, Derdelinckx I, Verhaegen J, Declerq E, Van Damme J, Peeters CL, Dierick K, Peeters CL, Dierick K, et al. Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in HIV-positive patients: a randomized and placebo controlled trial. Lancet 2000; 355: 2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1

[41] Peeters CL, Dierick K, Declerq E, Van Damme J, Peeters CL, Dierick K, et al. Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in HIV-positive patients: a randomized and placebo controlled trial. Lancet 2000; 355: 2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1

[42] Peeters CL, Dierick K, Declerq E, Van Damme J, Peeters CL, Dierick K, et al. Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in HIV-positive patients: a randomized and placebo controlled trial. Lancet 2000; 355: 2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1
[42] Jacob ST, Pavlinac PB, Nakijingi L, Banura P, Baeten JM, Morgan K, Magaret A, Manabe Y, Reynolds SJ, Liles WC, et al. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected patients hospitalized with severe sepsis in Uganda–high frequency, low clinical suspicion [corrected] and derivation of a clinical prediction score. PLoS One 2013; 8:e70305; PMID:23940557; http://dx.doi.org/10.1371/journal.pone.0070305

[43] Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32: 263-9; PMID:11170916; http://dx.doi.org/10.1086/318457

[44] Nadelman RB, Mathur-Wagh U, Yancovitz SR, Mildvan D. Salmonella bacteremia associated with the acquired immunodeficiency syndrome (AIDS). Arch Intern Med 1985; 145: 1968-71; PMID:3904653; http://dx.doi.org/10.1001/archinte.1985.00360110038010

[45] Celum CL, Chaisson RE, Rutherford GW, Barnhart JL, Echenberg DF. Incidence of salmonellosis in patients with AIDS. J Infect Dis 1987; 156: 998-1002; PMID:3680999; http://dx.doi.org/10.1093/infdis/156.6.998

[46] Gruenewald R, Blum S, Chan J. Relationship between human immunodeficiency virus infection and salmonellosis in 20- to 59-year-old residents of New York City. Clin Infect Dis 1994; 18: 358-63; PMID:8011816; http://dx.doi.org/10.1086/313358

[47] Gordon MA, Banda HT, Gondwe M, Gordon SB, Boeree MJ, Walsh AL, Corkill JE, Hart CA, Gilks CF, Molyneux ME. Non-typhoidal salmonella bacteremia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16: 1633-41; PMID:12172085; http://dx.doi.org/10.1093/infdis/156.9.998

[48] Gilks CF, Brindle RJ, Otieno LS, Simani PM, Newham RS, Bhatt SM, Lule GN, Okelo GB, Watkins WM, Waiyaki PG, et al. Life-threatening bacteremia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet 1990; 336: 545-9; PMID:1975046; http://dx.doi.org/10.1016/0140-6736(90)92096-Z

[49] Hung CC, Hung MN, Hseuh PR, Chang SY, Chen MY, Hsieh SM, Sheng WH, Sun HY, Huang YT, Lo YC, et al. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis 2007; 45: 60-7; PMID:17554702; http://dx.doi.org/10.1086/520681

[50] Peters RP, Ziljstra EE, Schijffelen MJ, Walsh AL, Joaki G, Kumwenda JI, Kublin JG, Molyneux ME, Lewis DK. A prospective study of bloodstream infections as cause of fever in Malawi: clinical predictors and implications for management. Trop Med Int Health 2004; 9: 928-34; PMID:15304000; http://dx.doi.org/10.1111/j.1365-3156.2004.01288.x

[51] Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 417-32; PMID:20510282; http://dx.doi.org/10.1016/S1473-3099(10)70072-4

[52] Meremo A, Mshana SE, Kidinya BR, Kabangila R, Peck R, Kataraihya JB. High prevalence of non-typhoid Salmonella bacteremia among febrile HIV adult patients admitted at a tertiary hospital, north-western Tanzania. Int Arch Med 2015; 47: 611-7; PMID:25875395; http://dx.doi.org/10.3109/23744235.2015.1033002

[53] Varma JK, McCarthy KD, Tansneeypayan T, Monkongdee P, Kimerling ME, Buntheoun E, Sculler D, Keo C, Phanuphak P, Teeratakulprasorn N, et al. Bloodstream infections among HIV-infected outpatients, Southeast Asia. Emerg Infect Dis 2010; 16: 1569-75; PMID:20875282; http://dx.doi.org/10.3201/eid1610.091686

[54] Kiertiburanakul S, Watcharitapagnor S, Chongtrakool P, Santanirand P. Epidemiology of bloodstream infections and predictive factors of mortality among HIV-infected adult patients in Thailand in the era of highly active antiretroviral therapy. Jpn J Infect Dis 2012; 65: 28-32; PMID:22274154

[55] Petrosillo N, Viale P, Nicastri E, Arici C, Bombana E, Casella A, Cristini F, De Gennaro M, Dodi F, Gabbuti A, et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin Infect Dis. 2002; 34: 677-85; PMID:11823956; http://dx.doi.org/10.1086/338813

[56] Bedell RA, Anderson ST, van Lettow M, Akesson A, Corbett EL, Kumwenda M, Chan AK, Heyderman RS, Zachariah R, Harries AD, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. PLoS One 2012; 7: 39347; http://dx.doi.org/10.1371/journal.pone.0039347

[57] Lewis DK, Peters RP, Schijffelen MJ, Joaki GR, Walsh AL, Kublin JG, Kumwenda J, Kampondeni S, Molyneux ME, Ziljstra EE. Clinical indicators of mycobacteremia in adults admitted to hospital in Blantyre, Malawi. Int J Tuberc Lung Dis 2002; 6: 1067-74; PMID:12546114

[58] Archibald IK, McDonald LG, Nwanyanwu O, Kazembe P, Dobbie H, Tokars J, Reller LB, Jarvis WR. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Infect Dis 2000; 181: 1414-20; PMID:10762572; http://dx.doi.org/10.1086/315367

[59] World Health Organization. Global Tuberculosis Report: 2012 [internet]. World Health Organization, Geneva, Switzerland; 1997 [updated 2014; cited 2015 Aug 25]. Available from: http://www.who.int/tb/publications/global_report/en/

[60] Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Zachariah R, Harries AD, et al. High prevalence of tuberculosis and serious bloodstream infections in sub-saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55: 242-50; PMID:22511551; http://dx.doi.org/10.1093/cid/cis409

[61] Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [internet] New York: Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America; 2015
[62] Crump JA, Morrissey AB, Ramadhani HO, Njau BN, Maro VP, Reller LB. Controlled comparison of BacT/ALERT MB system, manual MYCO/F LYTIC, and ISO-LATOR 10 system for detection of Mycobacterium tuberculosis bacteria. J Clin Microbiol 2011; 49: 3054-7; PMID:21653761; http://dx.doi.org/10.1128/JCM.01035-11

[63] Von Reyn CF. The significance of bacteremic tuberculosis among persons with HIV infection in developing countries. AIDS 1999; 13: 2193-5; PMID:10563704; http://dx.doi.org/10.1097/00002030-199911120-00001

[64] Garbino J, Kolarova L, Lew D, Hirschel B, Rohner P. Fungemia in HIV-infected patients: a 12-year study in a tertiary care hospital. AIDS Patient Care STDS 2001; 15: 407-10; PMID:11522214; http://dx.doi.org/10.1089/108729101316914403

[65] Hung CC, Chang SC. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother 2004; 54: 849-53; PMID:15456733; http://dx.doi.org/10.1093/jac/dkh438

[66] Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. French Cryptococcosis Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS 2004; 18: 555-62; PMID:15090810; http://dx.doi.org/10.1093/00000441-200402200-00024

[67] Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt M, Gardner T, Sattah M, de Leon GP, Baughman W, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-94; PMID:12627365; http://dx.doi.org/10.1086/368091

[68] Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, Souala F, Allavena C, Raffi F, Garre M, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815-22; PMID:9792382; http://dx.doi.org/10.1097/00002030-199814000-00013

[69] L. TARAMASSO ET AL.